March 18, 2019Blood Advances126 citationsOpen Access
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
Structured PICO
Do newer TKIs increase the risk of cardiovascular and arteriothrombotic adverse events compared to imatinib in chronic-phase CML patients?
P
Population
Chronic-phase CML (chronic myeloid leukemia) patients
I
Intervention
Newer TKIs (tyrosine kinase inhibitors), particularly ponatinib
C
Comparator
Imatinib 400
O
Outcome
Cardiovascular adverse events (CV-AEs) and arteriothrombotic adverse events (AT-AEs)safety
Newer TKIs, especially ponatinib, are associated with a significantly increased risk of cardiovascular and arteriothrombotic adverse events compared to imatinib in patients with chronic-phase CML, necessitating close vascular monitoring.
Abstract
< .0001) compared with imatinib 400. In summary, there is an increased risk of CV-AEs (except hypertension) and AT-AEs in CML patients treated with newer TKIs, particularly with ponatinib. Patients on TKIs must be informed and closely monitored for vascular AEs. These studies were registered at www.clinicaltrials.gov as #NCT00048672, #NCT00038649, #NCT00050531, #NCT00254423, #NCT00129740, and #NCT01570868.
Cite This Study
Jain et al. (Mon,) studied this question.